Literature DB >> 20874517

Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Ruy M Ribeiro1, Georgios Germanidis, Kimberly A Powers, Bertrand Pellegrin, Paul Nikolaidis, Alan S Perelson, Jean-Michel Pawlotsky.   

Abstract

BACKGROUND: Hepatitis B e antigen (HBeAg)–negative chronic hepatitis B infection has a presentation and clinical course that is divergent from that of HBeAg‐positive infection. The former usually presents with lower viral levels but faster progression to liver disease. We sought to better understand the balance between replication and the immune response against hepatitis B virus (HBV).
METHODS: Viral kinetics in 50 HBeAg‐negative patients under various treatment protocols with interferon α and/or nucleoside or nucleotide analogs was analyzed. HBV DNA level was measured frequently and the data fitted to a viral dynamic model. A meta‐analysis of all published studies of viral kinetics in HBeAg‐positive and HBeAg‐negative infection was also conducted.
RESULTS: We found that the clearance of both HBV virions and infected cells was significantly faster in HBeAg‐negative infection than in HBeAg‐positive infection. In HBeAg‐negative infection, there was also a negative correlation between baseline HBV DNA levels and infected cell half‐life, suggesting that the higher the viral load the faster the turnover of infected cells.
CONCLUSIONS: These results reveal the dual role played by the immune response in maintaining lower viral levels and inducing faster turnover of infected cells, the latter of which may be responsible for the more aggressive nature of HBeAg‐negative infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20874517      PMCID: PMC3058754          DOI: 10.1086/656528

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.

Authors:  Ulrike Mihm; Barbara Christine Gärtner; Dominik Faust; Wolf Peter Hofmann; Christoph Sarrazin; Stefan Zeuzem; Eva Herrmann
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

2.  Hepatitis B viral kinetics: a dynamic puzzle still to be resolved.

Authors:  Avidan U Neumann
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

3.  A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.

Authors:  Vassiliki-Anastasia Sypsa; Konstantinos Mimidis; Nicholas C Tassopoulos; Dimitrios Chrysagis; Themistoklis Vassiliadis; Antonios Moulakakis; Maria Raptopoulou; Caterina Haida; Angelos Hatzakis
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

4.  A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.

Authors:  Piero Colombatto; Luigi Civitano; Ranieri Bizzarri; Filippo Oliveri; Somesh Choudhury; Ronald Gieschke; Ferruccio Bonino; Maurizia R Brunetto
Journal:  Antivir Ther       Date:  2006

Review 5.  New kinetic models for the hepatitis C virus.

Authors:  Alan S Perelson; Eva Herrmann; Florence Micol; Stefan Zeuzem
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

Review 6.  Immunology of hepatitis B virus and hepatitis C virus infection.

Authors:  Barbara Rehermann; Michelina Nascimbeni
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

7.  Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays.

Authors:  Venkatakrishna Shyamala; Phillip Arcangel; Joshua Cottrell; Doris Coit; Angelica Medina-Selby; Colin McCoin; Dennis Madriaga; David Chien; Bruce Phelps
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

Review 8.  Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention.

Authors:  D Lavanchy
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

9.  Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.

Authors:  Sharon R Lewin; Ruy M Ribeiro; Anchalee Avihingsanon; Scott Bowden; Gail Matthews; Pip Marks; Stephen A Locarnini; Kiat Ruxrungtham; Alan S Perelson; Gregory J Dore
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection.

Authors:  Lars Frelin; Therese Wahlström; Amy E Tucker; Joyce Jones; Janice Hughes; Byung O Lee; Jean-Noel Billaud; Cory Peters; David Whitacre; Darrell Peterson; David R Milich
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

View more
  18 in total

1.  TGF-β signaling is activated in patients with chronic HBV infection and repressed by SMAD7 overexpression after successful antiviral treatment.

Authors:  Nikoletta Argentou; Georgios Germanidis; Prodromos Hytiroglou; Eirini Apostolou; Themistoklis Vassiliadis; Kalliopi Patsiaoura; Paschalis Sideras; Anastasios E Germenis; Matthaios Speletas
Journal:  Inflamm Res       Date:  2016-02-09       Impact factor: 4.575

2.  Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.

Authors:  Xue-Ping Nan; Ye Zhang; Hai-Tao Yu; Rui-Lin Sun; Mei-Juan Peng; Yu Li; Wen-Jing Su; Jian-Qi Lian; Jiu-Ping Wang; Xue-Fan Bai
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

3.  Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.

Authors:  Vladimir Reinharz; Alexander Churkin; Harel Dahari; Danny Barash
Journal:  Mathematics (Basel)       Date:  2022-06-19

4.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

Review 5.  Therapy of Delta Hepatitis.

Authors:  Cihan Yurdaydin; Ramazan Idilman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

Review 6.  Viral kinetic modeling: state of the art.

Authors:  Laetitia Canini; Alan S Perelson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-25       Impact factor: 2.745

7.  Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.

Authors:  K J Cortez; M A Proschan; L Barrett; D G Brust; Barry Weatherley; E Formentini; R T Davey; H Masur; M A Polis; A U Neumann And; S Kottilil
Journal:  HIV Clin Trials       Date:  2013 Jul-Aug

8.  Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice.

Authors:  Vladimir Reinharz; Yuji Ishida; Masataka Tsuge; Karina Durso-Cain; Tje Lin Chung; Chise Tateno; Alan S Perelson; Susan L Uprichard; Kazuaki Chayama; Harel Dahari
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

9.  Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.

Authors:  I Jane Cox; Abil E Aliev; Mary Me Crossey; Mahvish Dawood; Mamun Al-Mahtab; Sheikh M Akbar; Salimur Rahman; Antonio Riva; Roger Williams; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

10.  Liver FOXP3 and PD1/PDL1 Expression is Down-Regulated in Chronic HBV Hepatitis on Maintained Remission Related to the Degree of Inflammation.

Authors:  Georgios Germanidis; Nikoletta Argentou; Prodromos Hytiroglou; Themistoklis Vassiliadis; Kalliopi Patsiaoura; Anastasios E Germenis; Matthaios Speletas
Journal:  Front Immunol       Date:  2013-07-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.